During US military operations in Somalia, mefloquine, a drug for malaria chemoprophylaxis, was not approved for use in pregnant women. Some female soldiers inadvertently used mefloquine before becoming aware of their pregnancy. A registry was established to follow the outcomes of these pregnancies. Questionnaires were administered at the time the pregnancy was diagnosed, after termination or delivery, and at 1 year after birth. Seventy-two soldiers were eligible for the registry. There were 17 elective abortions, 12 spontaneous abortions, 1 molar pregnancy, and 23 live births. The outcome for 19 soldiers was unknown. An unexpected high rate of spontaneous abortions was observed. All infants were healthy at birth, with no major congenital malformations. One infant died at 4 months of viral pneumonitis. At 1 year of age, 13 infants were reported to be healthy, with normal cognitive and motor development. This study provides additional postmarketing data that mefloquine does not cause gross congenital malformations.
There are few antimalarial drugs that are effective and can While pregnant soldiers are not deployable, their fetuses may be inadvertently exposed to mefloquine if the soldier has not be used safely for chemoprophylaxis in pregnant women [1] . Mefloquine (Lariam, Hoffman-La Roche, Nutley, NJ), the recbecome aware of her condition before or during the deployment. This situation occurred when female soldiers were deommended drug for chemoprophylaxis in most malarious areas because of its effectiveness against chloroquine-resistant Plasployed to Somalia during Operations Restore Hope and Continue Hope, 1992 -1994. All soldiers, except those for whom modium falciparum [2], was not initially approved for use in pregnant women. Animal studies indicated some teratogenicity it was contraindicated, used mefloquine (250 mg each week) for malaria chemoprophylaxis. Loading doses of mefloquine in mice and rats at doses of 100 mg/kg/day [3] . This is much higher than the chemoprophylactic dosage for a 70-kg person were not used. Before the deployment, female soldiers were advised that mefloquine taken during pregnancy posed a potenof 0.5 mg/kg/day. One study in a refugee population indicated that mefloquine could be safely administered in the latter half tial risk to the fetus, that they should not become pregnant while on mefloquine, and that pregnancy should be delayed of pregnancy (ú20 weeks of gestation) [4] , but there are few data about its effect on the fetus during the first trimester.
for at least 2 months following the last dose of mefloquine. In March 1993, the Division of Preventive Medicine at Walter Although the risk to the human fetus is thought to be low, there is insufficient information available to establish the absoReed Army Institute of Research was asked by the US Army Office of the Surgeon General to establish a registry of all lute safety of mefloquine use during pregnancy [5] .
female soldiers who had been deployed to Somalia and had inadvertently taken mefloquine during pregnancy or shortly before conception. In this report, we will describe the outcome Received 14 October 1996; revised 24 March 1997.
of these pregnancies and the health of exposed infants.
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Informed consent was obtained from the women and for their children.
Methods
Human experimentation guidelines of the US Department of Defense were followed.
Upon laboratory confirmation of the pregnancy in Somalia,
The opinions and assertions contained herein are the private ones of the authors and are not to be construed as official or reflecting the views of the mefloquine chemoprophylaxis was discontinued, and the soldiers US Army or the Department of Defense.
were transported to nonmalarious areas. The names and social Each soldier was also informed of the registry. Army physicians exposed to mefloquine and to forward the soldiers' names and social security numbers to the registry. Information about the pregnancy, delivery, and infant was obtained from three questionnaires. The first, given when the soldier was first identified as pregnant, gathered demographic data and mefloquine exposure history. A second questionnaire was administered to collect information on the outcome of the pregnancy. If the soldier carried her baby to term, data were also collected on prior pregnancy histories and outcomes, the current pregnancy and delivery history, and the infant. The third questionnaire was completed 1 year after the birth of the infant and documented the health and development of the child. The questionnaires were completed by health care providers after a chart review or a tele- Figure 1 . Distributions of total doses of mefloquine taken by solphone interview with the soldier. Soldiers were considered lost to diers who had live births, elective abortions, and spontaneous aborfollow-up if we were unable after six attempts to contact them by tions. Box represents 25th and 75th percentiles; vertical line represents telephone or if the soldier had been discharged from the army. range; median is horizontal line. * Mean.
Results
One infant died at 4 months of age of viral pneumonitis. Seventy-two soldiers were identified as having used mefloThe cause of death was verified by autopsy, as noted on the quine during their pregnancy. Of these, 17 had elective abordeath certificate. Health information on 13 other infants was tions, 12 had spontaneous abortions, 1 had a molar pregnancy, obtained at 1 year of age. All were reported to be healthy and and 23 had live births. The outcome of the pregnancy was not had normal cognitive and motor development. Two of the 13 known for 19 of the 72 soldiers. Of these 19 soldiers, 14 had infants were reported to be small for their ages, but both had left the service before information about the pregnancy outsmall parents. Information was unavailable for 9 (39%) of the come could be obtained and 2 refused to participate. Three infants 1 year after their birth. Most of their mothers had left were still on active duty, but information could not be obtained.
the army. The molar pregnancy was diagnosed at 11 weeks of gestation in a black 22-year-old soldier. The ages of the 17 soldiers who had elective abortions ranged from 19 to 32 years (median, Discussion 23). Most were not married (n Å 12, 71%). Two were married and 1 was divorced. The marital status of 2 soldiers was unOur data add further information about the use of mefloquine in pregnant women. We observed no congenital malformations known.
The ages of the 12 soldiers who had spontaneous abortions in babies who were exposed to mefloquine in the first trimester, but this conclusion is limited by the small sample size. Our data ranged from 18 to 32 years (median, 22.5). The mean estimated gestational age at the time of the spontaneous abortion was 9.3 are consistent with the few reports in the literature. Balocco and Bonati [7] did not find any malformations or perinatal pathoweeks (range, 6 -12). The average number of mefloquine doses that the fetuses were exposed to was 5.7 (range, 2 -12). The logic symptoms in 11 babies born from 10 deliveries to mothers who had used mefloquine during the first trimester. In addition, total doses of mefloquine taken by soldiers who had spontaneous abortions was similar to that among soldiers who had live there were no congenital birth defects reported in a group of 99 travelers whose fetuses had been inadvertently exposed to births or elective abortions (analysis of variance, P Å .12; figure 1 ). The rate of spontaneous abortions (12/36) in this mefloquine in the first trimester [1] . The rate of spontaneous abortions observed in our registry is cohort was 33% (95% confidence interval, 19.5% -49.8%).
There were 23 live births. Fourteen soldiers (61%) were higher than that reported in other studies. Among the travelers mentioned above, the rate was 7.6% [1] . In a review of a single and 9 were married. Their ages ranged from 18 to 27 years (median, 21). Fourteen soldiers (61%) were primigravida. pharmaceutical database that monitored 331 European women who had inadvertently taken mefloquine during the first trimesThe average number of mefloquine doses that the fetuses were exposed to was 6.8 (range, 1 -16). There were 9 female infants ter, the rate was 9% [1] . This was not statistically different from the rate in women who had used other antimalarial drugs (39%). All of the infants were healthy at birth. Their average 1-and 5-min APGAR scores were 8.1 and 9.0, respectively.
or from a quoted 7% -12% background rate among women with clinically ascertained fetal loss. The infants' sizes were appropriate for their gestational age. Their weight ranged from 2693 to 4167 g. There were no There are several possible explanations for the higher rate of spontaneous abortions in our study. It may be a result of congenital malformations. Two abnormalities were noted on the neonatal physical examinations. One infant was jaundiced our close monitoring of all pregnancies that occurred within our cohort. This prospective surveillance system could note and the other had a pilonidal sinus. early pregnancy losses that might not have been reported in a first trimester to the Malaria Section, CDC, telephone (770) 488-7760 for continued assessment of pregnancy outpassive data collecting system. The rate may also be inflated by the high number of elective abortions that occurred. Had comes. these pregnancies progressed to normal deliveries, the denominator for the spontaneous abortion rate would have been
